Associate Professor in Medicine, Northwestern University Medical School
Internal Medicine
Dr. June M. McKoy, MD
|
|
Give Review
Dr. June M. McKoy works in the field of Internal Medicine. He went to University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago has a rank of 49 in research and a 85 in primary care He has 2 awards "Regional Top Doctor" and "Meaningful Use Stage 1 Certification". June McKoy is a published doctor and has 69 publications published. The lastest was: 'Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.' He is registered with Medicare and accepts Medicare payments.
Publications
- Elevated incidence of fractures in women with invasive breast cancer.
- Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
- Are Telehealth Technologies for Hypertension Care and Self-management Effective or Simply Risky and Costly?
- Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a research on adverse ...
- Improving Diversity in Cancer Research Trials: The Story of the Cancer Disparities Research Network.
- Assessing cognitive function and capacity in older adults with cancer.
- Reporting of serious adverse events during cancer clinical trials to the institutional review board: An evaluation by the Research on Adverse Drug events And Reports (...
- Costs and outcomes evaluation of patient navigation after abnormal cancer screening: Evidence From the Patient Navigation Research Program.
- Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.
- Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in...
- Results from the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project.
- Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.
- Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
- Bisphosphonates and Nonhealing Femoral Fractures: Analysis of the FDA Adverse Event Reporting System (FAERS) and International Safety Efforts: A Systematic Review from...
- Reducing the Risks of Diabetes Complications Through Diabetes Self-Management Education and Support.
- A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.
- Effects of Cancer Comorbidity on Disease Management: Making the Case for Diabetes Education (A Report from the SOAR Program).
- Temporal lobe epilepsy masquerading as dementia.
- Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States.
- A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
- Anticancer drug use in geriatric patients: concerns and challenges.
- Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.
- Evaluation of a potential clinical interaction between ceftriaxone and calcium.
- Reassessments of ESAs for cancer treatment in the US and Europe.
- Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumonia.
- Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening.
- Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
- Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared?
- Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
- Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (198...
- Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment.
- AIs: implications for fractures in perimenopausal women with breast cancer.
- Epoetin-associated pure red cell aplasia: past, present, and future considerations.
- Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
- Gadolinium-associated nephrogenic systemic fibrosis.
- Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin.
- Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening.
- Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
- Cost considerations in the management of cancer in the older patient.
- Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and phar...
- Visual hallucinations in an elderly woman: a presentation of Charles Bonnet syndrome?
- Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.
- Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
- Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.
- Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the...
- Opportunities for disease state management in prostate cancer.
- Patient preferences in prostate cancer: a clinician's guide to understanding health utilities.
- The Research on Adverse Drug Events and Reports (RADAR) project.
- Is ethics for sale?... Juggling law and ethics in managed care.
- Pure red-cell aplasia and epoetin therapy.
- Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.
- Monitoring in diabetes self-management: issues and recommendations for improvement.
- Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
- Senior adult oncology.
- Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia.
- Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from t...
- Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive ch...
- Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events an...
- Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
- Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
- Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
- Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
- Older patients'' perceptions of medication importance and worth: an exploratory pilot study.
- Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug event...
- Upping recruitment in clinical trials: are the costs worth it?
- Evaluating the cost-effectiveness of cancer patient navigation programs: conceptual and practical issues.
- Adverse drug interactions: moving from perception to action.
- Systematic review of piperacillin-induced neutropenia.
Schools
Southern Illinois University School Of Medicine
University Il College Of Med
Doctors Specialties
- Geriatric Medicine
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Bakery & Confectionary Union Plan
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Great West Healthcare-Cigna PPO
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Thrivent Financial
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
Education
-
University of Illinois College of Medicine at Chicago -
McGaw Medical Center of Northwestern University -
Kellogg School of Management, Northwestern University
Hospital
-
Northwestern Memorial Hospital
Drug Facts
| NPI NUMBER | 1164589917 | |
| NPPES Provider LastName | MCKOY | |
| NPPES Provider FirstName | JUNE | |
| NPPES Provider ZIPCode | 606112927 | |
| NPPES Provider State | IL | |
| Specialty Description | Geriatric Medicine | |
| Total Claim Count | 668.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164589917 |
| Last Name Of The Provider | MCKOY |
| First Name Of The Provider | JUNE |
| View All |
Similar Doctors
|
Dr. Ziauddin Ahmed, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David K. Edelberg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ismail E. Atcha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karim Dajani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kellie H. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saranya Biswas, MD |
|
|
Dr. Kimbra A. Bell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adnan Yousuf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Bergl, MD |